secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001104659-25-107753
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Q3 net loss $39.3M (-$0.62); cash $678.8M; icotrokinra filed, rusfertide NDA expected Q4
--------------------------------------------------------------------------------

- Net loss of $39.3M ($0.62 diluted EPS loss) vs $33.2M loss in Q3 2024.
- Cash $678.8M, up from $559.2M at year-end 2024; provides runway through at least end 2028.
- Icotrokinra NDA submitted to FDA (July) and EMA (September) for moderate-to-severe plaque psoriasis.
- Rusfertide granted FDA Breakthrough Therapy designation; Phase 3 VERIFY 52-week data at ASH Dec 2025; NDA filing expected Q4 2025.
- First patient dosed in Phase 1 for oral IL-17 antagonist PN-881.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465925107753/0001104659-25-107753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465925107753/tm2530353d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer